[go: up one dir, main page]

ZA9710796B - Oxyiminopregnanecarbolactones. - Google Patents

Oxyiminopregnanecarbolactones.

Info

Publication number
ZA9710796B
ZA9710796B ZA9710796A ZA9710796A ZA9710796B ZA 9710796 B ZA9710796 B ZA 9710796B ZA 9710796 A ZA9710796 A ZA 9710796A ZA 9710796 A ZA9710796 A ZA 9710796A ZA 9710796 B ZA9710796 B ZA 9710796B
Authority
ZA
South Africa
Prior art keywords
oxyiminopregnanecarbolactones
oxyiminopregnane
carbolactones
formula
production
Prior art date
Application number
ZA9710796A
Other languages
English (en)
Inventor
Henry Laurent
Ralph Lipp Peter Esperling
Johannes-Wilhelm Tack
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of ZA9710796B publication Critical patent/ZA9710796B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA9710796A 1996-12-01 1997-12-01 Oxyiminopregnanecarbolactones. ZA9710796B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19651000A DE19651000A1 (de) 1996-12-01 1996-12-01 Oxyiminopregnancarbolactone

Publications (1)

Publication Number Publication Date
ZA9710796B true ZA9710796B (en) 1998-06-12

Family

ID=7814054

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9710796A ZA9710796B (en) 1996-12-01 1997-12-01 Oxyiminopregnanecarbolactones.

Country Status (10)

Country Link
US (1) US6177416B1 (xx)
EP (1) EP0944643B1 (xx)
AT (1) ATE233274T1 (xx)
AU (1) AU5485698A (xx)
CA (1) CA2273354C (xx)
DE (2) DE19651000A1 (xx)
DK (1) DK0944643T3 (xx)
ES (1) ES2191208T3 (xx)
WO (1) WO1998024801A1 (xx)
ZA (1) ZA9710796B (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE429231T1 (de) 1999-08-31 2009-05-15 Bayer Schering Pharma Ag Pharmazeutische kombination von ethinylestradiol und drospirenon als empfängnisverhütendes mittel
US6787531B1 (en) 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
EP2305267A3 (en) 1999-08-31 2011-08-17 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
EP1406634A1 (en) 2001-07-13 2004-04-14 Schering Aktiengesellschaft Combination of drospirenone and an estrogen sulphamate for hrt
IL164808A0 (en) * 2002-04-26 2005-12-18 Schering Ag Treatment of hypertesion in women receiving hormone replacement therapy
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
US20050222106A1 (en) * 2004-04-01 2005-10-06 Stefan Bracht Drospirenone-containing preparations for transdermal use
DE102004016779A1 (de) * 2004-04-01 2006-01-19 Schering Ag Drospirenonhaltige Zubereitungen zur transdermalen Anwendung
DE102004063864A1 (de) * 2004-12-30 2006-07-13 Schering Ag 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
US8445469B2 (en) * 2004-12-30 2013-05-21 Bayer Intellectual Property Gmbh 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter
DE102006030416A1 (de) * 2006-06-29 2008-01-03 Bayer Schering Pharma Ag 18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate
DE102007027636A1 (de) * 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007027635A1 (de) 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-19-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007027637A1 (de) 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
TW200927141A (en) * 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
DE102007063496A1 (de) 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15,16-Methylen-17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063500A1 (de) 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 17-(1'-Propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063501A1 (de) 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15, 16-Methylen-17-hydroxy-19-nor-21-carbonsäure-Steroid y-Lacton-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063498A1 (de) 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15,16-Methylen-steroid-17,17-Lactol-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063503A1 (de) 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-19-nor-21-carbonsäure-Steroid y-Lacton-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063495A1 (de) 2007-12-29 2009-09-17 Bayer Schering Pharma Aktiengesellschaft 19-Nor-Steroidderivate mit einer 15α,16α-Methylengruppe und einem gesättigten 17,17-Spirolactonring, deren Verwendung sowie diese Derivate enthaltende Arzneimittel
DE102007063499A1 (de) 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft Steroid-17,17-Lactol-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
WO2010066349A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Verwendung von 17beta-cyano-19-androst-4-en-derivaten zur herstellung eines arzneimittels in depot-form zur parenteralen anwendung sowie depot-arzneimittel enthaltend 17beta-cyano-19-androst-4-en-derivate zur parenteralen anwendung
WO2010066355A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft VERWENDUNG VON 17β- CYANO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG
WO2010066354A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft VERWENDUNG VON 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG
CA2759667A1 (en) 2009-02-18 2010-08-26 Bayer Pharma Aktiengesellschaft Particles comprising drospirenone encapsulated in a polymer
EP2398461A1 (en) 2009-02-18 2011-12-28 Bayer Pharma Aktiengesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
CN102985076A (zh) * 2010-04-15 2013-03-20 拜耳知识产权有限责任公司 用于hrt的低剂量的固体口服剂型
SI3630724T1 (sl) 2017-05-22 2021-08-31 Janssen Pharmaceuticals, Inc. Substituirani derivati indolina kot zaviralci replikacije virusa denga

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3022337A1 (de) * 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
DE3916112A1 (de) * 1989-05-16 1990-11-22 Schering Ag Dihydrospirorenon als antiandrogen
IL115659A (en) * 1994-10-27 2000-06-01 Akzo Nobel Nv Steroids with a 17-spiromethylene lactone or lactol group process for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
EP0944643B1 (de) 2003-02-26
WO1998024801A1 (de) 1998-06-11
DE59709414D1 (de) 2003-04-03
AU5485698A (en) 1998-06-29
DE19651000A1 (de) 1998-06-04
US6177416B1 (en) 2001-01-23
EP0944643A1 (de) 1999-09-29
DK0944643T3 (da) 2003-05-05
CA2273354A1 (en) 1998-06-11
ES2191208T3 (es) 2003-09-01
CA2273354C (en) 2009-06-09
ATE233274T1 (de) 2003-03-15

Similar Documents

Publication Publication Date Title
ZA9710796B (en) Oxyiminopregnanecarbolactones.
MX9700885A (es) Nuevas heteroariloxazolidinonas.
AU6613896A (en) Chemical compounds
EP1193270A3 (en) Pyrrolobenzodiazepines
AP2002002637A0 (en) Novel piperazine
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
MY120511A (en) New pesticides
IL123293A0 (en) Piperidine derivatives their preparation and use
AU5377698A (en) Substituted pyrrolyl compounds for the treatment of inflammation
IT1285770B1 (it) Composti corticoidei
BG103310A (en) Benzonaphthyridins as bronchial therapeutical means
HRP930239A2 (en) Anti-inflamatory 4-aminophenol derivatives
BG103399A (en) New heterocycle-substituted benzamides and their application for the treatment of diseases
MY133969A (en) Indoloquinazolinones
UA49884C2 (uk) ПОХІДНІ <font face="Symbol">a</font>-ГІДРОКСИКАРБОНОВОЇ КИСЛОТИ ТА ЛІКАРСЬКИЙ ЗАСІБ НА ЇХ ОСНОВІ
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
MX9708696A (es) Cefalosporinas antibacterianas.
AU7027100A (en) Novel compounds
MY125674A (en) Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis
TR199701298T1 (xx) Tetralinler.
NZ504614A (en) Echinocandin derivatives and application as anti-fungal agents
ZA983231B (en) Substituted benzyloxyimino compounds.
BR9606955A (pt) Heterocicloalquenos substituísos
AU6722498A (en) Disubstituted biphenyloxazolines
PT1104419E (pt) Derivados de azabicicloheptano substituidos no azoto sua preparacao e utilizacao